Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen

Cancer Research

Volumn 67, Issue 6, 2007, Pages 2881-2892

  Saha, Asim ^a   Chatterjee, Sunil K ^a   Foon, Kenneth A ^b   Celis, Esteban ^c   Bhattacharya Chatterjee, Malaya ^a,d  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; ANTIIDIOTYPIC ANTIBODY 3H1; CARCINOEMBRYONIC ANTIGEN; CHROMIUM 51; CYTOKINE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; HLA A2 ANTIGEN; ISOLEUCYLMETHIONYLISOLEUCYLGLYCYLVALYLLEUCYLVALYLGLYCYLVALINE; PEPTIDE DERIVATIVE; TYROSYLLEUCYLSERYLGLYCYLALANYLASPARAGINYLLEUCYLASPARAGINYLLEUCINE; TYROSYLLEUCYLSERYLGLYCYLALANYLASPARTYLLEUCYLASPARAGINYLLEUCINE; TYROSYLMETHIONYLISOLEUCYLGLYCYLMETHIONYLLEUCYLVALYLGLYCYLVALINE; TYROSYLMETHIONYLISOLEUCYLGLYCYLVALYLLEUCYLLEUCYLGLYCYLVALINE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; COLON CARCINOMA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; EXPERIMENTAL NEOPLASM; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COLONIC NEOPLASMS; DENDRITIC CELLS; EPITOPES; FEMALE; HLA-A2 ANTIGEN; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ADOPTIVE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 34047266237     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3045     Document Type: Article

References (51)

1. Ochsenbein AF. Principles of tumor immunosurveillance and implications for immuno-therapy. Cancer Gene Ther 2002;9:1043-55.
2. Zorn E, Hercend T. A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion. Eur J Immunol 1999;29:602-7.
3. Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995;154:3961-8.
4. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996;29:371-80.
5. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-7.
6. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
7. Carbone FR, Kurts C, Bennett SR, Miller JF, Heath WR. Cross-presentation: a general mechanism for CTL immunity and tolerance. Immunol Today 1998;19:368-73.
8. + T cell responses in antitumor immunity. Curr Opin Immunol 1998;10:588-94.
9. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998;187:693-702.
10. + T cells in the antitumor immune response. J Exp Med 1998;188:2357-68.
11. Toes RE, Ossendorp F, Offringa R, Melief CJ. CD4 T cells and their role in antitumor immune responses. J Exp Med 1999;189:753-6.
12. + T cell response depending on the route of immunization. J Immunol 1998;160:5522-9.
13. + T lymphocytes. Nature 2003;421:852-6.
14. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003;300:337-9.
15. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
16. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
17. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000;18:245-73.
18. Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 1991;5:344-66.
19. Berinstein NL. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol 2002;20:2197-207.
20. Bhattacharya-Chatterjee M, Mukherjee S, Biddle W, Foon KA, Kohler H. Murine monoclonal anti-idiotype antibody as a potential network antigen for human carcinoembryonic antigen. J Immunol 1990;145:2758-65.
21. Saha A, Chatterjee SK, Foon KA, et al. Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice. Cancer Res 2004;64:4995-5003.
22. Saha A, Baral RN, Chatterjee SK, et al. CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice. Cancer Immunol Immunother 2006;55:515-27.
23. Saha A, Chatterjee SK, Foon KA, Bhattacharya-Chatterjee M. Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen. Immunology 2006;118:483-96. Erratum in: Immunology 2006;119:143.
24. Bhattacharya-Chatterjee M, Chatterjee SK, Foon KA. Anti-idiotype antibody vaccine therapy for cancer. Expert Opin Biol Ther 2002;2:869-81.
25. Kawashima I, Hudson SJ, Tsai V, et al. The multiepitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 1998;59:1-14.
26. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995;87:982-90.
27. Clarke P, Mann J, Simpson JF, Rickard-Dickson K, Primus FJ. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res 1998;58:1469-77.
28. H response. Hum Immunol 2000;61:764-79.
29. Lu J, Higashimoto Y, Appella E, Celis E. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J Immunol 2004;172:4575-82.
30. Horig H, Wainstein A, Long L, et al. A new mouse model for evaluating the immunotherapy of human colorectal cancer. Cancer Res 2001;61:8520-6.
31. Vitiello A, Marchesini D, Furze J, Sherman LA, Chesnut RW. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J Exp Med 1991;173:1007-15.
32. Tangri S, Ishioka GY, Huang X, et al. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J Exp Med 2001;194:833-46.
33. Huarte E, Sarobe P, Lu J, et al. Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements. Clin Cancer Res 2002;8:2336-44.
34. Liao YP, Wang CC, Butterfield LH, et al. Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells. J Immunol 2004;173:2462-9.
35. + T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity. Eur J Immunol 2004;34:752-61.
36. Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY, Schlom J. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 1997;57:4570-7.
37. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD, Jr. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J Exp Med 1996;183:283-7.
38. Tong Y, Song W, Crystal RG. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res 2001;61:7530-5.
39. Melief CJ, Toes RE, Medema JP, van der Burg SH, Ossendorp F, Offringa R. Strategies for immunotherapy of cancer. Adv Immunol 2000;75:235-82.
40. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998;188:2199-204.
41. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNγ receptor expression by nonhematopoietic cells. Immunity 2000;12:677-86.
42. Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med 1994;179:1215-24.
43. Wan Y, Bramson J, Pilon A, Zhu Q, Gauldie J. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines. Cancer Res 2000;60:3247-53.
44. Saha A, Chatterjee SK, Foon KA, Primus FJ, Bhattacharya-Chatterjee M. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity. Cancer Res 2003;63:2844-54.
45. Fong L, Hou Y, Rivas A, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A 2001;98:8809-14.
46. + T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J Immunol 2000;165:6047-55.
47. Zhou H, Luo Y, Mizutani M, et al. A novel transgenic mouse model for immunological evaluation of carcinoembryonic antigen-based DNA minigene vaccines. J Clin Invest 2004;113:1792-8.
48. Dai S, Wan T, Wang B, et al. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells. Clin Cancer Res 2005;11:7554-63.
49. Huang Y, Fayad R, Smock A, Ullrich AM, Qiao L. Induction of mucosal and systemic immune responses against human carcinoembryonic antigen by an oral vaccine. Cancer Res 2005;65:6990-9.
50. Lanier LL. Follow the leader: NK cell receptors for classical and nonclassical MHC class I. Cell 1998;92:705-7.
51. Chan SH, Kobayashi M, Santoli D, Perussia B, Trinchieri G. Mechanisms of IFN-γ induction by natural killer cell stimulatory factor (NKSF/IL-12). Role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2. J Immunol 1992;148:92-8.